| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Agenus Inc.$3.35
+0.11 (+3.4%)
C 52Pipeline Score Fair Value Biotech · Commercial
Market Cap
140.75 M
EPS
1.74
P/E Ratio
2.02 $
Value Trade
1.54 M
SEC Financials
Q1 2026Dilution Risk
Revenue
33.74 M
R&D Expenses
11.82 M
Operating CF
-35.95 M
Total Assets
186.46 M
Total Liabilities
186.46 M
Equity
-221.22 M
D/E Ratio
12,345
-11.65 %
Week
-22.06 %
1 Month
-2.51 %
3 Month
-27.17 %
6 Month
-96.33 %
5 Year
-99.94 %
All Time
Cash Data
Cash Position
35.00 M
Monthly Burn
11.98 M
Runway
0.9 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
833.40 K
52 Week Range
2.71 - 7.34
% held by Insiders
9.28 %
% held by Institutions
19.75 %
Enterprise Value
403.46 M
Total Shares
38.38 M
Short %
16.87 %
Float Shares
35.54 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Agenus Inc.
793Total events
5Upcoming
210Tier-1 (high impact)
2010 – 2026Coverage
Upcoming catalysts 5
Event history 788
Jul 7, 2026
▲Oral PresentationBotensilimabPresentation
Presentazione dei dati di riferimento a tre anni dello studio BOT+BAL a ESMO GI 2026
carcinoma colorettale metastatico MSS refrattario senza metastasi epatiche attivesource ↗
Jul 6, 2026
▲Oral PresentationPresentation
Presentatie van BOT+BAL resultaten op ESMO GI 2026
refractair MSS-gemetastaseerd colorectaal carcinoom zonder actieve levermetastasensource ↗
Jul 6, 2026
▲Oral PresentationBotensilimabPresentation
Landmark BOT+BAL data showing 33% three-year overall survival presented at ESMO GI 2026
refractory MSS metastatic colorectal cancer without active liver metastasessource ↗
Jul 6, 2026
▲Oral PresentationBotensilimabPresentation
Presentation of 3-year Phase 1b data for BOT+BAL at ESMO GI 2026
refractory MSS metastatic colorectal cancer without active liver metastasessource ↗
Jul 2, 2026
▲Oral PresentationBotensilimabPresentation
Three-year landmark Phase 1b data for BOT+BAL presented at ESMO GI 2026
refractory microsatellite-stable metastatic colorectal cancer without active liver metastasessource ↗
Jul 2, 2026
▲Full ResultsBotensilimabClinical Data
Three-year overall survival data: 33% at 36 months, median OS 21.2 months
refractory microsatellite-stable metastatic colorectal cancer without active liver metastasessource ↗
Jul 2, 2026
▲Primary Endpoint MetBotensilimabClinical Data
Primary safety and tolerability endpoint met; no new safety signals
refractory microsatellite-stable metastatic colorectal cancer without active liver metastasessource ↗
Jul 2, 2026
▲Secondary Endpoint DataBotensilimabClinical Data
Secondary endpoints: ORR 21%, DCR 69%, median DOR not reached
refractory microsatellite-stable metastatic colorectal cancer without active liver metastasessource ↗
Jul 2, 2026
▲Subgroup AnalysisBotensilimabClinical Data
Post hoc late-line-exposed subgroup analysis
refractory microsatellite-stable metastatic colorectal cancer without active liver metastasessource ↗
Jun 25, 2026
◆Oral PresentationBotensilimabPresentation
Three-year survival data from Phase 1b BOT+BAL study in MSS mCRC to be presented at ESMO GI 2026
MSS metastatic colorectal cancersource ↗
Jun 2026
◆Timing GuidancePresentation
Webcast at Annual Shareholder Meeting in June 2026 to provide strategic updates
Drug Pipeline Intelligence
C52
Pipeline Score $106M
Pipeline ValueFair Value
Valuation Signal22
Drugs Scored0.8x
rNPV / MCap Top 79%
Micro Cap (rank 193 of 912)
Percentile RankAgenus Inc. carries a moderate pipeline score (52/100), with $6.1B risk-adjusted pipeline value, led by AGEN1571 in Advanced Solid Tumor (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGEN1571 Small molecule | Advanced Solid Tumor | Phase 1 | NCT05377528 | 5% | $1.6B | COMPLETED | 22 | - | - | Dec 23, 2024 | - | Apr 30, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
— | metastatic MSS colorectal cancer | — | 2026-07-07 | 33% | Riassunto: Agenus condivide ad ESMO GI 2026 dati storici dello studio BOT+BAL che evidenziano una sopravvivenza globale a tre anni del 33% al carcinoma colorettale metastatico MSS refrattario senza metastasi epatiche attive Read More | |
— | metastatic MSS colorectal cancer | — | 2026-07-07 | 33% | Riassunto: Agenus condivide ad ESMO GI 2026 dati storici dello studio BOT+BAL che evidenziano una sopravvivenza globale a tre anni del 33% al carcinoma colorettale metastatico MSS refrattario senza metastasi epatiche attive Read More | |
— | metastatic MSS colorectal cancer | — | 2026-07-07 | 33% | Riassunto: Agenus condivide ad ESMO GI 2026 dati storici dello studio BOT+BAL che evidenziano una sopravvivenza globale a tre anni del 33% al carcinoma colorettale metastatico MSS refrattario senza metastasi epatiche attive Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AGEN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AGEN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AGENRiassunto: Agenus condivide ad ESMO GI 2026 dati storici dello studio BOT+BAL che evidenziano una sopravvivenza globale a tre anni del 33% al carcinoma colorettale metastatico MSS refrattario senza metastasi epatiche attive
Agenus presented historical data from the BOT+BAL study at ESMO GI 2026, highlighting a three-year overall survival rate of 33% for patients with metastatic MSS colorectal cancer without active liver metastases. The findings contribute to the ongoing research in colorectal cancer treatment.
Read more →AGENSamenvatting: Agenus presenteert op ESMO GI 2026 veelbelovende resultaten van BOT+BAL: 33% totale overleving na drie jaar bij refractair MSS-gemetastaseerd colorectaal carcinoom zonder actieve levermetastasen
Agenus showcased promising results at the ESMO GI 2026 conference, highlighting a 33% overall survival rate after three years for patients with refractory MSS metastatic colorectal carcinoma without active liver metastases. This data underscores the potential of their BOT+BAL treatment in this challenging patient population.
Read more →AGENAgenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
Agenus has announced promising data from its BOT+BAL study, showing a 33% overall survival rate at three years for patients with refractory MSS metastatic colorectal cancer without active liver metastases. This data was presented at the ESMO GI 2026 conference, marking a significant milestone for the company in addressing this challenging cancer type.
Read more →AGENAgenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
Agenus has announced that it will present three-year survival data from its Phase 1b BOT+BAL study focused on MSS metastatic colorectal cancer at the upcoming ESMO GI 2026 conference. This presentation is expected to provide insights into the efficacy of their treatment approach. Further details about the study and outcomes are anticipated during the event.
Read more →AGENAgenus Announces Virtual 2026 Annual Shareholders Meeting
Agenus has announced that it will hold its 2026 Annual Shareholders Meeting virtually. This decision reflects the company's commitment to ensuring safety and accessibility for its shareholders. Further details about the meeting's agenda and participation will likely be provided closer to the date.
Read more →AGENAgenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Agenus presented data on their Phase 2 BOT+BAL melanoma treatment at ASCO 2026. The results indicated durable responses and meaningful survival rates in patients with advanced checkpoint-refractory melanoma. Further details on the efficacy and safety of the treatment were discussed during the presentation.
Read more →AGENAgenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
Agenus and Noetik are set to present data at ASCO 2026, focusing on the use of AI to analyze routine pretreatment tumor pathology images. The study aims to link these analyses to patient response and survival rates when treated with BOT+BAL in MSS metastatic colorectal cancer. Further details about the findings and implications are expected during the presentation.
Read more →AGEN▼ -14.7%on this news
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development • Authorized access interest continues to expand across regio
Agenus Inc. reported positive first quarter 2026 financial results and updates on its lead clinical program, BOT+BAL, which has advanced into Phase 3 trials. The company has expanded access to BOT+BAL through regulatory pathways and a strategic collaboration with Zydus, enhancing its financial stability and manufacturing capacity. The Phase 3 BATTMAN trial began patient enrollment in April 2026, supporting further clinical investigation into the effectiveness of the drug combination in colorectal cancer. The growing interest and active enrollment underscore the potential of BOT+BAL to enhance patient outcomes in challenging therapeutic areas.
Read more →AGEN▼ -14.7%on this news
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
Agenus has reported its financial results for the first quarter of 2026, highlighting its ongoing efforts in executing the BOT+BAL strategy across global access and Phase 3 development. The report emphasizes the company's focus on advancing its clinical programs and expanding market reach. Further details on financial performance and strategic initiatives were also discussed.
Read more →AGENAgenus to Provide First Quarter 2026 Financial Report and Corporate Update
Agenus has announced plans to release its financial report for the first quarter of 2026 along with a corporate update. The specific details regarding the financial performance or corporate developments have not been disclosed in the announcement. This update is anticipated by stakeholders for insights into the company's progress.
Read more →AGENAgenus ernennt BAP Pharma zum exklusiven globalen Partner für die BOT+BAL-Zugangsprogramme
Agenus has appointed BAP Pharma as its exclusive global partner for the BOT+BAL access programs. This partnership aims to facilitate patient access to these therapies through authorized channels, addressing the urgent need for effective cancer treatments. BAP Pharma will coordinate global activities related to the access programs, enhancing logistics and compliance. The collaboration reflects a strong commitment to patient care and regulatory adherence.
Read more →AGENAgenus nomeia a BAP Pharma como parceira global exclusiva para os programas de acesso BOT+BAL
Agenus has appointed BAP Pharma as its exclusive global partner for the BOT and BAL access programs. This partnership aims to facilitate patient access to these treatments through authorized channels, complying with local regulations. The collaboration is driven by significant interest from healthcare professionals and aims to support patients with advanced cancers. BAP Pharma will manage logistics and coordination for these global access initiatives.
Read more →AGENAgenus designa a BAP Pharma como socio global exclusivo para BOT+BAL
Agenus has appointed BAP Pharma as its exclusive global partner for the BOT+BAL combination therapy. This collaboration will enhance the operational framework for managing access to these therapies, which are currently available through a French state-funded program and individual access schemes in selected countries. The partnership aims to address the growing demand for innovative cancer treatments.
Read more →AGENRiassunto: Agenus nomina BAP Pharma partner esclusivo globale per i programmi di accesso a BOT+BAL
Agenus has appointed BAP Pharma as its exclusive global partner for authorized access programs for botensilimab (BOT) and balstilimab (BAL). This partnership aims to enhance patient-centered access to these therapies through compliant pathways. BAP Pharma will manage the coordination of global access operations, including program requests and logistics.
Read more →AGENAgenus désigne BAP Pharma comme partenaire mondial exclusif pour les programmes d’accès à la combinaison BOT+BAL
Agenus has appointed BAP Pharma as its exclusive global partner for access programs involving the combination of botensilimab (BOT) and balstilimab (BAL). This partnership aims to ensure patient-centered access to these treatments through authorized pathways. BAP Pharma will manage logistics, distribution, and payment processing for these programs, which are already attracting significant interest from physicians across multiple countries.
Read more →AGENSamenvatting: Agenus benoemt BAP Pharma tot exclusieve wereldwijde partner voor de BOT+BAL-toegangsprogramma’s
Agenus has appointed BAP Pharma as its exclusive global partner for the BOT+BAL access programs. This partnership aims to ensure compliant, patient-centered access to the therapies through authorized channels. BAP Pharma will coordinate global activities related to the access programs, including case coordination and logistics.
Read more →AGENAgenus指定BAP Pharma為BOT聯合BAL療法取得計畫的全球獨家合作夥伴
Agenus Inc. has announced a partnership with BAP Pharma to develop and distribute their combined therapies, botensilimab (BOT) and balstilimab (BAL). This collaboration aims to enhance access to innovative treatments globally, focusing on patients with difficult-to-treat cancers. The agreement is set to improve the efficiency of drug development and regulatory processes.
Read more →AGEN▼ -11.5%on this newsshared move
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
Agenus announced the acceptance of four abstracts for presentation at the 2026 ASCO Annual Meeting, including the first Phase 2 data for botensilimab in advanced cutaneous melanoma. The data will focus on patients resistant to anti-PD-(L)1 therapy. The presentations underscore Agenus' commitment to developing new immunotherapy options.
Read more →AGEN▼ -11.5%on this newsshared move
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
Agenus has appointed BAP Pharma as its exclusive global partner for the botensilimab (BOT) and balstilimab (BAL) access programs. This partnership will facilitate patient access to these therapies through authorized pathways, including France's AAC program and paid named-patient programs in select countries. The collaboration aims to address the urgent need for effective cancer treatments and enhance operational efficiency in accessing these therapies.
Read more →AGEN▲ +13.2%on this news· ran to +34% by day 3
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
Agenus has announced that data from a Phase II trial evaluating botensilimab and balstilimab in combination with agenT-797 will be presented at the AACR Annual Meeting in April 2026. This study focuses on patients with PD-1 refractory gastroesophageal cancer, addressing a critical area of unmet need. The trial aims to enhance immune responses in challenging tumor types.
Read more →AGENAgenus inicia el ensayo global de fase 3 BATTMAN con la inclusión del primer paciente para la combinación inmunoterapéutica BOT+BAL en cáncer colorrectal metastásico MSS o pMMR
Agenus has initiated the global Phase 3 BATTMAN trial, enrolling its first patient to evaluate the combination of botensilimab (BOT) and balstilimab (BAL) in patients with unresectable, refractory metastatic colorectal cancer. The trial, led by the Canadian Cancer Trials Group, aims to include around 830 patients across multiple countries and is designed to support regulatory approval for the BOT+BAL combination.
Read more →AGENAgenus annonce le recrutement du premier patient dans l’essai mondial de phase III BATTMAN portant sur l’association immunothérapeutique BOT+BAL dans le cadre du cancer colorectal métastatique MSS ou pMMR
Agenus has announced the recruitment of the first patient in the Phase III BATTMAN trial, which evaluates the combination of botensilimab and balstilimab for treating metastatic colorectal cancer. This trial aims to provide new treatment options for patients with microsatellite stable cancer, a group historically resistant to immunotherapy. The study will involve over 830 patients across multiple countries, indicating strong interest from the medical community.
Read more →AGENRiassunto: Agenus annuncia il primo paziente registrato in BATTMAN, il trial clinico globale di fase 3 sulla combinazione di immunoterapia BOT+BAL nel cancro del colorettale in fase avanzata MSS o pMMR
Agenus Inc. has announced the enrollment of the first patient in the Phase 3 BATTMAN trial. This global study evaluates the immunotherapy combination of botensilimab (BOT) and balstilimab (BAL) in patients with metastatic colorectal cancer (mCRC) who are refractory and non-resectable. The trial targets a population historically resistant to immunotherapy, specifically those with microsatellite stability (MSS) and proficient mismatch repair (pMMR).
Read more →AGENA Agenus anuncia a inclusão do primeiro paciente no estudo global de fase 3 BATTMAN, que avalia a combinação de imunoterapia BOT+BAL em câncer colorretal metastático MSS ou pMMR
Agenus has announced the enrollment of the first patient in the Phase 3 BATTMAN study, which evaluates the combination of botensilimab (BOT) and balstilimab (BAL) in patients with refractory and unresectable metastatic colorectal cancer. The study is being conducted globally with over 100 centers participating, aiming to recruit approximately 830 patients. This trial represents a significant step towards developing effective immunotherapies for patients with limited treatment options.
Read more →AGENSamenvatting: Agenus kondigt inschrijving eerste patiënt aan voor wereldwijde Fase 3 BATTMAN-studie naar BOT+BAL-immunotherapiecombinatie bij MSS- of pMMR-gemetastaseerde colorectale kanker
Agenus Inc. has announced the enrollment of the first patient in its Phase 3 BATTMAN study, which evaluates the combination of botensilimab (BOT) and balstilimab (BAL) against optimal supportive care. This study focuses on patients with refractory, unresectable MSS/pMMR metastatic colorectal cancer, a group previously deemed resistant to immunotherapy. The trial aims to explore new treatment avenues for this challenging cancer type.
Read more →AGENAgenus宣布BOT+BAL聯合免疫療法用於MSS或pMMR轉移性大腸直腸癌的全球第三期BATTMAN試驗完成首例病患招募
Agenus Inc. has announced the successful completion of the BATTMAN trial, which tested the combination of botensilimab (BOT) and balstilimab (BAL) for treating microsatellite stable (MSS) and mismatch repair deficient (pMMR) metastatic colorectal cancer (mCRC). This trial, led by the Canadian Cancer Trials Group, involved over 100 research centers across multiple countries. The results are expected to contribute significantly to the development of effective treatments for these challenging cancer types.
Read more →AGENAgenus gibt die Aufnahme des ersten Patienten in die globale Phase-3-Studie BATTMAN bekannt, in der die Immuntherapie-Kombination aus BOT und BAL bei metastasiertem kolorektalem Karzinom der MSS- oder pMMR-Gruppe untersucht wird
Agenus has announced the enrollment of the first patient in the global Phase 3 BATTMAN study, which evaluates the combination of Botensilimab (BOT) and Balstilimab (BAL) in treating metastatic colorectal cancer. The study aims to provide effective immunotherapy options for patients with microsatellite stable (MSS) or proficient mismatch repair (pMMR) tumors, a group historically resistant to such therapies. Conducted by the Canadian Cancer Trials Group, the study will include approximately 830 patients across multiple countries.
Read more →AGENAgenus宣布BOT+BAL联合免疫疗法用于MSS或pMMR转移性结直肠癌的全球3期BATTMAN试验完成首例患者入组
Agenus Inc. announced the successful completion of the BATTMAN trial, which evaluated the combination of botensilimab (BOT) and balstilimab (BAL) for treating microsatellite stable (MSS) and mismatch repair deficient (pMMR) metastatic colorectal cancer (mCRC). The trial involved over 830 participants and demonstrated promising efficacy for patients with limited treatment options. This collaboration with the Canadian Cancer Trials Group and other organizations marks a significant milestone for Agenus.
Read more →AGENAgenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Agenus has announced the enrollment of the first patient in its global Phase 3 BATTMAN trial, which evaluates the combination of botensilimab and balstilimab in patients with MSS/pMMR metastatic colorectal cancer. This trial aims to provide effective immunotherapy options for patients who have historically been resistant to such treatments. The study will involve over 100 sites across multiple countries and aims to enroll approximately 830 patients.
Read more →AGENAgenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
Agenus Inc. will host a Stakeholder Webcast on March 31, 2026, to discuss the progress of its BOT+BAL immunotherapy program. The session will cover updates on patient access initiatives and development across various tumor types. Moderated by CEO Garo H. Armen, the event will also include a live Q&A segment.
Read more →AGEN▼ -5.8%on this news
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
Agenus Inc. announced that preliminary results from a study evaluating botensilimab and balstilimab in first-line microsatellite stable colorectal cancer will be presented at the AACR Annual Meeting 2026. This study aims to improve treatment outcomes for patients historically resistant to immunotherapy. The trial has been expanded to Phase 2, indicating a significant advancement in immuno-oncology research.
Read more →AGEN▲ +6.1%on this news· ran to +29% by day 1shared move
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized • Early access programs expand globally: 200+ physician inq
Agenus Inc. has reported positive progress in its BOT+BAL immunotherapy program, highlighting a global Phase 3 trial for refractory metastatic colorectal cancer (mCRC) and the expansion of early access programs. The company recognized $4.2 million in initial revenue from these programs, which are designed to provide treatment to patients who have exhausted approved therapies. Clinical data indicates a significant survival benefit in mCRC patients, while a collaboration with Zydus enhances its production capabilities. The company's strategic priorities include advancing regulatory filings and further expanding patient access.
Read more →AGEN▲ +6.1%on this news· ran to +29% by day 1shared move
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
Agenus Inc. reported its 2025 financial results, highlighting the advancement of its BOT+BAL immunotherapy program into Phase 3 trials for metastatic colorectal cancer. The program has gained traction through early access initiatives, generating initial revenues while expanding patient access. Clinical data supports its efficacy in difficult-to-treat cancers, reinforcing its potential as a new immunotherapy franchise.
Read more →AGEN▼ -8.8%on this news
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
Agenus Inc. announced it will release its fourth quarter and year-end 2025 financial results on March 16, 2026. The company will also host a stakeholder briefing to discuss strategic plans and updates on its botensilimab and balstilimab development programs. Both therapies have shown promise in clinical trials for various cancers.
Read more →AGENAgenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors
Agenus Inc. announced that new biomarker analyses from its botensilimab program will be presented at the AACR-IO Conference in February 2026. The study focuses on the relationship between systemic inflammation and clinical outcomes in patients with treatment-refractory tumors. Botensilimab, in combination with balstilimab, aims to enhance immune responses against these challenging cancers.
Read more →AGENAgenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
Agenus has expanded its global Medical Affairs infrastructure to address the rising demand from physicians for access to the investigational immunotherapy combination of botensilimab and balstilimab. This decision comes in response to increasing inquiries from oncologists regarding early access pathways for patients with advanced solid tumors. The company aims to ensure that these requests are supported with scientific rigor and regulatory compliance.
Read more →AGENAgenus to Host First 2026 Stakeholder Webcast
Agenus Inc. will host its first Stakeholder Webcast of 2026 on January 28, focusing on the BOT+BAL program's global momentum. The session will discuss access pathways, strategic partnerships, and clinical development, featuring insights from company leadership and an oncology expert. This event marks the beginning of Agenus' 2026 Stakeholder Briefing Series.
Read more →AGEN▼ -9.2%on this newsshared move
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.
Zydus Lifesciences Limited has successfully acquired Agenus Inc.'s biologics manufacturing facilities, launching a new subsidiary, Zylidac Bio LLC, in the U.S. This acquisition enhances Zydus' capabilities in the global biologics CDMO sector and allows Agenus to focus on its immunotherapy pipeline. The deal also aligns with the BIOSECURE Act, promoting secure domestic manufacturing.
Read more →AGEN▼ -9.2%on this newsshared move
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
Agenus has finalized a strategic collaboration with Zydus Lifesciences, securing $141 million to advance its BOT+BAL immunotherapy program. This partnership enhances Agenus' manufacturing capabilities in the U.S. and grants Zydus exclusive rights to develop these therapies in India and Sri Lanka. The collaboration aims to accelerate clinical development and commercialization efforts.
Read more →AGEN▼ -9.2%on this newsshared move
About Balstilimab (BAL) Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been eval
Agenus Inc. has finalized a $141 million strategic partnership with Zydus Lifesciences to enhance the development of its immunotherapy program, BOT+BAL. The collaboration includes a cash payment for manufacturing facilities and exclusive development rights in India and Sri Lanka. Agenus aims to advance its Phase 3 trials and expand patient access to its BOT+BAL therapy, which has shown encouraging clinical results in colorectal cancer. This deal also establishes U.S.-based biologics manufacturing capacity to support future commercialization.
Read more →AGENAgenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
Agenus has published promising results from its Phase 1b C-800-01 trial, showing that the combination of botensilimab and balstilimab (BOT+BAL) achieved a 23% overall response rate in patients with treatment-refractory ovarian cancer. The treatment resulted in durable responses and improved overall survival rates, indicating its potential in a population with few remaining options. These findings support further development of BOT+BAL in larger studies.
Read more →AGEN▲ +5.8%on this news
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances • France grants reimbursed access with patients having commenced treatment • Two-year BOT/BAL survival presen
Agenus reported positive Q3 2025 results, highlighting clinical and regulatory advances for its immunotherapy products. Notably, France has granted reimbursed access for botensilimab plus balstilimab (BOT/BAL). The company presented promising survival data at ESMO, indicating significant outcomes in patients with advanced solid tumors. Additionally, the Phase 3 BATTMAN trial is set to launch in Q4 2025, aiming to evaluate BOT/BAL compared to standard supportive care in unresectable colorectal cancer.
Read more →AGEN▼ -11%on this news
Agenus is dedicated to making investigational medicines available to patients with cancer at the appropriate time and in the correct manner. For more information, visit www.agenusbio.com/medical-affairs/ . About Botensil
Agenus Inc. announced its financial results for Q2 2025, highlighting significant clinical, regulatory, and operational milestones, particularly for their BOT/BAL immunotherapy combination. The company secured a collaboration with Zydus Lifesciences, resulting in a $91 million capital infusion, and is set to initiate a Phase 3 trial for BOT/BAL in Q4 2025 after aligning with FDA regulations. Recent trial results demonstrated a 42% two-year survival rate in refractory colorectal cancer, enhancing confidence in the treatment's potential. A virtual stakeholder meeting is scheduled for August 27, 2025, to discuss these advancements.
Read more →AGEN▲ +12.6%on this news
PD-L2. It has been evaluated in 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types. Forward-Looking Statements This press release contains forward-look
Agenus Inc. has entered a $141 million strategic collaboration with Zydus Lifesciences to advance its immuno-oncology treatments, particularly botensilimab and balstilimab (BOT/BAL). The deal includes a $75 million upfront payment and potential additional payments based on production orders. This partnership aims to streamline the manufacturing process and enhance access to these therapies in India and Sri Lanka, where Zydus will hold exclusive rights for commercialization of BOT and BAL. Zydus is also making a $16 million equity investment in Agenus, reflecting a strong mutual commitment to the partnership.
Read more →AGEN▲ +20.3%on this news
Information that may be important to investors will be routinely posted on our website and social media channels. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant t
Agenus Inc. reported financial results for Q1 2025, highlighting advancements in its BOT and BAL programs within the immuno-oncology space. Notable achievements include demonstrating strong response rates in MSS cancers and the appointment of Dr. Richard Goldberg as Chief Development Officer to enhance development efforts. The company is set to reduce its operating cash burn and is nearing a collaboration expected to provide substantial cash infusion. Despite challenges, including a reported net loss and decreased cash reserves, the outlook remains positive as Agenus moves closer to critical regulatory milestones.
Read more →AGENAgenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“
Agenus Inc. reported its Q4 and year-end results for 2024, showcasing strategic operational improvements and significant cost reductions aimed at enhancing its BOT/BAL program. The company plans to reduce its annualized operational burn to approximately $50 million by mid-2025 through various cost-cutting measures. Clinical data revealed promising outcomes for its BOT/BAL program, particularly in hard-to-treat tumor types. However, Agenus remains challenged by a substantial net loss and a decrease in cash reserves compared to the previous year.
Read more →AGENAgenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment LEXINGTON, Mass.--(BUSINESS WIRE) -- Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncol
Agenus Inc. has secured a $22 million mortgage to improve its cash position and is implementing a strategic operational realignment focused on its botensilimab/balstilimab (BOT/BAL) program for MSS colorectal cancer. The alignment plan aims for a 60% reduction in external expenditures and transitions to a fee-for-service business model. With promising clinical data, the company targets key regulatory pathways for their oncology therapies. This restructuring seeks to establish a solid foundation for sustained growth and enhanced patient outcomes.
Read more →AGEN▼ -20.4%on this news
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations LEXINGTON, Mass.--(BUSINESS WIRE)
Agenus Inc. reported its financial results for Q3 2024, showcasing advancements in its BOT/BAL cancer therapies, particularly in MSS colorectal cancer. The promising clinical results have established BOT/BAL as a significant contender in immunotherapy, with further data expected to emerge from numerous studies. While the company is committed to expanding patient access through innovative treatment programs, it also grapples with substantial net losses and financial hurdles. Agenus remains focused on operational efficiencies and asset monetization to secure its financial foundation for future growth.
Read more →AGENAgenus Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 5, 2024 Deadline to file Lead Plaintiff Motion
The Portnoy Law Firm has notified investors in Agenus Inc. about a class action lawsuit for those who purchased shares between January 23, 2023, and July 17, 2024. The lawsuit alleges that Agenus misrepresented the efficacy of its drug combination treatments, balstilimab and botensilimab, leading to significant financial losses. Following a negative outcome from an FDA meeting regarding the drugs, Agenus' stock price fell nearly 59%, prompting the legal action. Investors have until November 5, 2024, to file a lead plaintiff motion.
Read more →AGENAgenus Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before November 5, 2024 to Discuss Your Rights – AGEN
Agenus Inc. is facing a class action lawsuit alleging securities fraud due to misleading statements regarding its immuno-oncology products. Specifically, the complaint claims that the effectiveness of botensilimab and balstilimab was exaggerated and their clinical results were not as favorable as presented. Shareholders who purchased shares during the specified class period from January 23, 2023, to July 17, 2024, are encouraged to participate by registering with The Gross Law Firm before the November 5, 2024 deadline. The lawsuit aims to protect investor rights amid claims of deception that led to inflated stock prices.
Read more →AGENAGENUS INC. (NASDAQ: AGEN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Agenus Inc. Investors of Upcoming Deadline
Bernstein Liebhard LLP is alerting Agenus Inc. investors about an upcoming deadline related to a securities fraud class action lawsuit. This lawsuit, filed in the U.S. District Court for Massachusetts, concerns misrepresentations made by Agenus about its investigational therapy for metastatic colorectal cancer. Investors who purchased shares from January 23, 2023, to July 17, 2024, are urged to discuss their legal rights and potential involvement. The deadline to apply as a lead plaintiff is set for November 5, 2024.
Read more →AGENAgenus Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 5, 2024 to Discuss Your Rights – AGEN
Agenus Inc. is being sued for securities law violations based on allegations that the company issued misleading statements regarding the effectiveness of its immuno-oncology therapies, botensilimab and balstilimab. The complaint claims that during the class period from January 23, 2023, to July 17, 2024, the company overstated clinical results and prospects, resulting in false public statements. Shareholders who purchased AGEN shares within this timeframe are encouraged to contact The Gross Law Firm for potential lead plaintiff appointments in this class action case, with a registration deadline set for November 5, 2024.
Read more →AGENAgenus Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – AGEN
Agenus Inc. is currently being sued for securities law violations, with allegations that the company misled investors regarding the effectiveness of their immuno-oncology products, botensilimab and balstilimab. The class period in question spans from January 23, 2023, to July 17, 2024. Shareholders are encouraged to register for a class action lawsuit that aims to address these alleged misrepresentations. The deadline to seek lead plaintiff status is November 5, 2024.
Read more →AGENAgenus Inc. Class Action Reminder - AGEN Stockholders with Large Losses They Should Contact Shareholder Rights Law Firm Robbins LLP for Information About the Agenus Inc. Class Action Lawsuit
Robbins LLP has announced a class action lawsuit against Agenus Inc. (NASDAQ: AGEN) on behalf of shareholders who acquired its securities between January 2023 and July 2024. The lawsuit alleges that Agenus misled investors about the effectiveness of its drug candidates, particularly regarding the combination therapy of botensilimab and balstilimab. This was highlighted by a significant drop in stock price following the FDA's statement against advancing their immunotherapy for colorectal cancer due to concerns over survival benefits.
Read more →AGENAgenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights – AGEN
Agenus Inc. is currently involved in a class action securities lawsuit filed by Levi & Korsinsky, LLP on behalf of investors who suffered losses due to alleged securities fraud. This legal action concerns claims that the company's immuno-oncology products, botensilimab and balstilimab, were inaccurately portrayed as more effective than they are. Investors have until November 5, 2024, to involve themselves in the case and potentially recover damages. The allegations suggest that Agenus' prior statements regarding its products' clinical and commercial prospects were misleading.
Read more →AGENAgenus Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights – AGEN
Agenus Inc. is facing a class action securities lawsuit led by Levi & Korsinsky, LLP, filed on behalf of investors adversely affected by alleged securities fraud. The complaint claims that the defendants misrepresented the effectiveness of their immuno-oncology products, botensilimab and balstilimab, leading to materially false public statements. Investors who suffered losses during the specified timeframe can contact the firm to discuss their rights and seek compensation. The deadline to request to be appointed as lead plaintiff is November 5, 2024.
Read more →AGEN▲ +5.1%on this newsshared move
AGENUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Agenus Inc. and Encourages Investors to Contact the Firm
Agenus Inc. is facing a class action lawsuit filed by Bragar Eagel & Squire, P.C. in the U.S. District Court for Massachusetts. The lawsuit pertains to claims that the company made false and misleading statements about its combination therapy of botensilimab and balstilimab during the class period from January 23, 2023, to July 17, 2024. Investors are encouraged to apply as lead plaintiff by November 5, 2024, as the complaint outlines significant concerns over the clinical efficacy and future prospects of the therapies.
Read more →AGENAgenus Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 5, 2024 Deadline to file Lead Plaintiff Motion.
Agenus Inc. is facing a class action lawsuit from investors who purchased securities between January 2023 and July 2024. The lawsuit alleges that Agenus made misleading statements about their treatments, balstilimab and botensilimab, which were found to be less effective than claimed. Following a disappointing meeting with the FDA concerning regulatory approval, Agenus' stock has seen a dramatic decline of nearly 59%. Investors are encouraged to contact the Portnoy Law Firm to explore their options for recovering losses.
Read more →AGENAGENUS INC. (NASDAQ: AGEN) INVESTOR ALERT: Investors With Large Losses in Agenus Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
A shareholder has filed a class action lawsuit against Agenus Inc. (NASDAQ: AGEN) on behalf of investors who purchased the company's securities between January 23, 2023, and July 17, 2024. The lawsuit alleges that Agenus made misrepresentations regarding its investigational therapy for metastatic colorectal cancer. Investors are advised that they can take legal action and that no fees or expenses will be incurred unless they participate in the litigation. Those interested in serving as a lead plaintiff must file by November 5, 2024.
Read more →AGENAgenus Reports Second Quarter 2024 Operational and Financial Results Robust Phase 2 Data Validate Consistent Clinical Activity of BOT/BAL in Metastatic MSS CRC Maturing Data Across BOT/BAL Program Demonstrate Broad Solid
Agenus Inc. reported its second-quarter financial results, highlighting substantial advances in its BOT/BAL program for colorectal cancer. The company noted robust interim data supporting its Phase 2 trial, demonstrating durable tumor reductions. Agenus is also launching a Named Patient Program to provide early access to BOT/BAL for patients with limited treatment options. Despite a significant net loss, the firm continues to seek partnerships and has recently closed part of its $75 million financing, indicating ongoing interest in its pipeline.
Read more →AGENAgenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors 6/17/2024 Strategic leadership to drive next phase of growth for the company LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus&#x
Agenus Inc. has appointed Dr. Jennifer Buell to its Board of Directors, a move aimed at strengthening the company's strategic leadership as it enters a new phase of growth. Dr. Buell, who continues to serve as President and CEO of MiNK Therapeutics, brings over 27 years of experience in the biopharmaceutical industry. Her previous contributions to Agenus include spearheading initiatives that enhanced the company's operational capabilities and strategic partnerships. Her appointment is expected to be pivotal as Agenus focuses on advancing its innovative oncology pipeline and aims for a Biologics License Application for its BOT/BAL program this year.
Read more →AGEN▼ -7.3%on this news· ran to -19% by day 3
Agenus Reports First Quarter 2024 Results $100M royalty financing agreement with Ligand announced, bringing in capital via non-equity means to support critical botensilimab/balstilimab (BOT/BAL) development and launch re
Agenus Inc. reported its Q1 2024 financial results, highlighting a $100 million royalty financing agreement with Ligand to support the development of its lead programs, botensilimab and balstilimab (BOT/BAL). The company has shown notable clinical results in early trials for treating metastatic colorectal cancer. Agenus also noted an improvement in its cash management, achieving compliance with Nasdaq listing requirements. Financially, the company recorded a loss of $63.5 million for the quarter while continuing to advance its clinical and commercial initiatives.
Read more →AGEN▼ -7.3%on this news· ran to -19% by day 3
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement Capital infusion will support botensilimab and balstilimab (BOT/BAL) clinical development, confirmatory Phase 3 trial, and launc
Ligand Pharmaceuticals and Agenus have established a royalty financing agreement worth $100 million to support the clinical development of the investigational therapies botensilimab and balstilimab (BOT/BAL). This financial infusion will aid Agenus in its Phase 3 trial for patients with specific colorectal cancer types and other launch activities. Furthermore, Ligand has the option to invest an additional $25 million, reinforcing their joint commitment to advancing cancer treatments. The agreement also stipulates that Ligand will earn royalties from future sales, highlighting the potential upside of this collaboration.
Read more →AGEN▼ -8.9%on this news
Agenus Reports Fourth Quarter and Full Year 2023 Results FDA Grants Fast Track designation for BOT/BAL in metastatic, refractory colorectal cancer (CRC) patients who have failed 1 st and 2 nd line standard of care treatm
Agenus Inc. reported its financial results for the fourth quarter and full year 2023, highlighting significant progress in the development of its BOT/BAL therapy. The FDA granted Fast Track designation for BOT/BAL in patients with metastatic, refractory colorectal cancer. Promising clinical data indicated a 24% response rate and a 74% overall survival rate at 12 months for the treatment. Despite these advances, the company reported substantial financial losses, including a net loss of $257 million for the year, alongside common adverse effects linked to treatment. Upcoming data from Phase 2 studies is expected in the second half of 2024.
Read more →AGEN▼ -29.5%on this news
expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties
Agenus is proposing a reverse stock split at a 1-for-20 ratio to comply with Nasdaq listing standards and enhance shareholder value. This proactive move aims to increase the stock price above $1, preventing potential selling by index funds. The company cites significant progress in clinical trials for its lead product, botensilimab, which has shown durable activity in treating solid tumors. Further, Agenus is exploring opportunities for partnerships and monetization of assets to support its growth strategy.
Read more →AGENAgenus Reports Third Quarter 2023 Results Conference Call on Tuesday
Agenus Inc. reported its third quarter 2023 results, highlighting significant developments in its cancer treatment pipeline, particularly with botensilimab (BOT) and balstilimab (BAL). Promising data from various clinical trials suggest strong efficacy in treating advanced solid tumors, including colorectal, pancreatic, lung, melanoma, and sarcoma. The company plans to submit a Biologics License Application to the FDA for MSS metastatic colorectal cancer in mid-2024. Despite these advancements, Agenus reported a substantial net loss of $64.5 million for the quarter, raising concerns about its financial stability moving forward.
Read more →AGEN▼ -8.1%on this news
Agenus Reports Second Quarter 2023 Results LEXINGTON, Mass.--(BUSINESS WIRE)
Agenus Inc. announced its second quarter 2023 financial results, highlighting significant advancements in their cancer treatment pipeline. The botensilimab/balstilimab combination has shown superior clinical outcomes compared to standard care, earning Fast Track designation from the U.S. FDA. The company also revealed promising Phase 1 data for AGEN2373 in patients with advanced solid tumors. Despite these achievements, Agenus reported a net loss of $73.4 million for the quarter.
Read more →AGEN▼ -5.7%on this news
Agenus Provides Corporate Update and First Quarter 2023 Financial Results At a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month overall survival rate in metastatic c
Agenus Inc. provided a corporate update and first quarter 2023 financial results, highlighting the promising efficacy of the botensilimab/balstilimab combination in treating metastatic colorectal cancer. The treatment demonstrated a notable 63% overall survival rate, which is significantly higher than existing therapies. The FDA has granted Fast Track Designation for this combination, expediting its potential approval. However, the company reported a substantial net loss during the same period, raising concerns about financial sustainability amid clinical development phases.
Read more →AGEN▼ -7.1%on this news
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
Agenus Inc. has announced a dividend of 5 million shares of its subsidiary, MiNK Therapeutics, to its shareholders as of April 17, 2023. This decision highlights Agenus's confidence in MiNK's clinical-stage precision oncology therapies, particularly its allogeneic natural killer T cell treatments. The distribution aims to enhance shareholder value and encourage participation in MiNK's future developments, which include upcoming clinical data presentations at the AACR Annual Meeting in April 2023. Shareholders will receive cash for any fractional shares instead of partial stock allocations.
Read more →AGENAgenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
Agenus Inc. reported its financial results for Q4 and full year 2022, highlighting strong momentum in its immuno-oncology pipeline. The company emphasized the potential of botensilimab and balstilimab in treating resistant cancers, supported by promising clinical trial data. Despite a significant net loss, Agenus aims to expedite the development of its therapies in 2023.
Read more →AGEN▲ +14%on this newsshared move
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
Agenus has canceled its scheduled conference call regarding its minority cash holdings at Silicon Valley Bank due to the government's announcement about deposit access. The call was originally set for March 13, 2023. Agenus is a clinical-stage immuno-oncology company focused on developing therapies to activate the immune system against cancer and infections.
Read more →AGEN▲ +14%on this newsshared move
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
Agenus has announced a conference call scheduled for March 13, 2023, to discuss its minority cash holdings at Silicon Valley Bank. The call will provide details and address any investor questions. Agenus is a clinical-stage immuno-oncology company dedicated to developing therapies that activate the immune system against cancer and infections.
Read more →AGENAgenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
Agenus announced it will present updated data on botensilimab at the SGO 2023 Annual Meeting. The data focuses on its use in combination with balstilimab for patients with recurrent platinum refractory ovarian cancer. The presentation is scheduled for March 27, 2023, and aims to showcase the therapy's efficacy and mechanism of action.
Read more →AGENAgenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
Agenus announced it will release its fourth quarter and full year 2022 financial results on March 14, 2023. The company will host a conference call and webcast to discuss these results and provide a corporate update. Agenus focuses on developing immunological therapies targeting cancer and infectious diseases.
Read more →AGENAgenus to Participate in February Investor Conferences
Agenus announced its participation in upcoming investor conferences, featuring presentations by Dr. Garo Armen and Dr. Steven O'Day. The live webcasts will be available on the company's website, with replays posted afterward. Agenus is dedicated to developing immunological agents for cancer and infectious diseases.
Read more →AGEN▼ -5.6%on this newsshared move
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Agenus presented promising clinical data on the combination of botensilimab and balstilimab for treating metastatic microsatellite stable colorectal cancer (MSS CRC) at the ASCO GI symposium. The Phase 1b study involved 70 patients and showed a 23% response rate, indicating significant efficacy compared to existing treatments. The company aims to advance this combination into global randomized trials.
Read more →AGEN▲ +11.4%on this news· ran to +24% by day 3
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
Agenus announced its participation in the B Riley Securities’ 2023 Virtual Oncology Conference. Dr. Garo Armen and Dr. Steven O’Day will lead a virtual fireside chat on January 18th. The event will be accessible via webcast, with an archived version available later on the company's website.
Read more →AGENAgenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
Agenus Inc. announced it will present expanded data on botensilimab combined with balstilimab at the ASCO-GI symposium from January 19-21, 2023. The data comes from a Phase 1 study focusing on microsatellite stable colorectal cancer. The presentation is set for January 21, 2023, at 10:00am ET.
Read more →AGENAgenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma
Agenus has presented expanded data from its Phase 1 study of botensilimab and balstilimab, showing strong durability and efficacy in advanced sarcoma patients. The combination therapy outperformed standard care and other investigational treatments, particularly in historically unresponsive sarcoma subtypes. The results will be discussed at the CTOS 2022 Annual Meeting, with plans for further Phase 2 trials.
Read more →AGENAgenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will
Read more →AGEN▲ +16.7%on this newsshared move
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
Overall response rates ranged from 22% in microsatellite stable colorectal cancer (MSS-CRC) to 60% in PD-(L)1 refractory non-small cell lung cancer (NSCLC) Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS-CRC and advanced melanoma; pancreatic cancer to follow be
Read more →AGEN▼ -6.7%on this news
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
Company to present expanded data from Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) at plenary session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS colorectal cancer and advanced
Read more →AGENAgenus to Provide Corporate Update and Third Quarter 2022 Financial Report
Conference Call on Tuesday, November 8, 2022, at 8:30 a.m. ET Company to host “The Road Taken” R&D Event in Boston on November 12 from 2p.m. – 5p.m. ET to discuss with oncology experts clinical experience to date and expected development plans for botensilimab in cold tumors LE
Read more →AGEN▲ +7.2%on this news· ran to +27% by day 1
Agenus to Host “The Road Taken” R&D Event on November 12, 2022
LEXINGTON, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced it will host an in-person and virtual Research & De
Read more →AGEN▲ +7.2%on this news· ran to +27% by day 1
Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Clinical data in nine cancer indications from trial with 264 patients accrued Plenary discussion relating to expansion cohorts represent heavily pretreated patients Additional SITC presentations cover 1) botensilimab’s differentiated mechanism; 2) Phase 2 trial of anti-CD73-TGF
Read more →AGENAgenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma
Phase 2 ACTIVATE trials to advance globally in metastatic patients who have progressed on available therapies Botensilimab, alone and in combination with balstilimab (PD-1), has demonstrated robust clinical activity in nine treatment-resistant tumor types, including microsatelli
Read more →AGENAgenus Makes Senior Regulatory and Clinical Appointments
Patricia Carlos named Chief Regulatory, Quality, and Safety Officer Todd Yancey, MD named Senior Global Clinical Development, Medical Affairs and Commercial Advisor LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an ex
Read more →AGENAgenus Provides Corporate Update and Second Quarter 2022 Financial Report
Botensilimab (Fc-enhanced CTLA-4)/balstilimab (PD-1) combination data presented at the 2022 ESMO World GI Congress demonstrated remarkable clinical activity in microsatellite stable colorectal cancer (MSS CRC) Agenus expects to present additional botensilimab expansion cohort da
Read more →AGENAgenus to Participate at BTIG Biotechnology Conference
LEXINGTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will attend the BTIG Biotechnology Conf
Read more →AGENAgenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid Tumors
Study will evaluate safety and tolerability of AGEN1571 as a single agent and in combination with botensilimab and balstilimab Preclinical data support best-in-class potential of AGEN1571 LEXINGTON, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq: AGEN), an immuno-
Read more →AGENAgenus to Provide Corporate Update and Second Quarter 2022 Financial Report
LEXINGTON, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN) an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced it will release its second quarter 2022 financial re
Read more →AGENAgenus to Participate at William Blair’s Biotech Focus Conference
LEXINGTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that Dr. Steven O’Day, Chief Medical Officer, will
Read more →AGEN▲ +10.9%on this news· ran to +31% by day 3shared move
Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress
Overall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4 prior lines of therapy Responses to botensilimab/balstilimab were durable, with 80% ongoing at data cut-off and median duration of response not reached Global, rand
Read more →AGEN▲ +5.1%on this news· ran to +21% by day 3
Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress
LEXINGTON, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will host a hybrid webcast to discuss b
Read more →AGENAgenus Advances Portfolio with 6 Clinical Collaborations
LEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that it has entered into 3 new clinical collabo
Read more →AGENAgenus Announces Virtual Annual Shareholders Meeting
LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that its Annual Shareholders Meeting will begin at 3
Read more →AGENAgenus to Participate at Jefferies Healthcare Conference
LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that Dr. Garo Armen, Chairman and CEO of Agenus and
Read more →AGEN▼ -8.3%on this newsshared move
Agenus Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance Botensilimab
Data to be Presented in Heavily Pretreated MSS-CRC Speed and Innovation Core to Development Strategy Reduction of 20% in 2022 Operating Costs LEXINGTON, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of
Read more →AGEN▲ +9.2%on this news
Agenus Corporate Update and First Quarter 2022 Financial Report
Botensilimab data to be presented and Phase 2 trials to launch. AGEN1571 (ILT2) clinical trials to commence and data presented at AACR. AGEN2373 progressing in the clinic and Gilead milestone payment received. LEXINGTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NAS
Read more →AGEN▼ -7%on this news
Agenus to Provide Corporate Update and First Quarter 2022 Financial Report
LEXINGTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its
Read more →AGENAgenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance
First data presentation on AGEN1571 shows strong adaptive and innate immune responses Preclinical data indicate superior performance to the only clinical-stage competitor Monotherapy activity and broad combination potential Investigational New Drug (IND) application cleared; c
Read more →AGENAgenus’ CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead
LEXINGTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, today announced receipt of a $5M clinical milestone payment for A
Read more →AGENAgenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report Botensilimab (Fc-enhanced) is the first anti-CTLA-4 antibody to demonstrate clinical responses across 9 cold, treatment-resistant cancers; Phas
Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report LEXINGTON, Mass., March 1, 2022 (GLOBE NEWSWIRE) Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies and adjuvants designed to activate immune res
Read more →AGEN▲ +8.9%on this news
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2021 Financial Report
LEXINGTON, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its f
Read more →AGEN▼ -6.2%on this news
Agenus to Participate at Upcoming Investor Conferences
LEXINGTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that management will
Read more →AGENAgenus to Participate in 4th Annual Evercore ISI HealthCONx Conference
LEXINGTON, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Garo Ar
Read more →AGEN▲ +6.5%on this news
Agenus to Participate in Fireside Chat at the B. Riley Fall 2021 Growth Biotech Best Ideas Series
LEXINGTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven
Read more →AGEN▲ +6.5%on this news
Agenus Corporate Update and Third Quarter 2021 Financial Report
Clinical results presented at SITC show that AGEN1181, as a monotherapy and in combination with balstilimab, shows durable responses in 9 cancer types, including patients whose cancers have recurred following PD-1 therapy Agenus will commence Phase 2/3 trials of AGEN1181 and bal
Read more →AGENAgenus to Participate in Webcast Hosted by William Blair to Discuss AGEN1181 Clinical Data from SITC 2021 Meeting
LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that
Read more →AGEN▼ -5.5%on this news
Agenus to Provide Corporate Update and Third Quarter 2021 Financial Report
LEXINGTON, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that
Read more →AGEN▼ -21.8%on this newsshared move
Agenus Provides Update on Balstilimab Development Company voluntarily withdraws BLA at FDA s recommendation following full approval of pembrolizumab, which came four months earlier than FDA goal date Balstilimab achieved
Agenus Provides Update on Balstilimab Development LEXINGTON, Mass., October 22, 2021 /GLOBENEWSWIRE/ Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune respon
Read more →AGEN▼ -21.8%on this newsshared move
Agenus Provides Update on Balstilimab Development
Company voluntarily withdraws BLA at FDA’s recommendation following full approval of pembrolizumab, which came four months earlier than FDA goal date Balstilimab achieved trial endpoints with 20% response rates in PD-L1 positive patients, versus 14% reported in pembrolizumab’s l
Read more →AGENAgenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced
Read more →AGENAgenus to Present AGEN1181 Clinical Data at SITC
LEXINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced
Read more →AGENAgenus to Participate in September Investor Conferences
LEXINGTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that
Read more →AGENAgenus Corporate Update and Second Quarter 2021 Financial Report
$200M received from BMS for anti-TIGIT bispecific antibody collaboration FDA cleared IND for AGEN1777 clinical enrollment AGEN1181 rapidly advancing in the clinic; data to be presented in 2H 2021 Cell therapy subsidiary MiNK Therapeutics filed confidential S-1 for planned IPO
Read more →AGENAgenus to Participate in the BTIG Virtual Biotechnology Conference 2021
LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that
Read more →AGEN▼ -5.7%on this news
Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report
LEXINGTON, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that
Read more →AGENAgenus Acquires 120 Acres in the Heart of the California Biomanufacturing Center in Vacaville
VACAVILLE, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. has purchased 120-acres in Vacaville’s California Biomanufacturing Center from housing developer A.G. Spanos, a transaction that represents a major advance in the city’s plans to expand its biotechnology footprint a
Read more →AGENAgenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021
LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that
Read more →AGENAgenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777
LEXINGTON, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infect
Read more →AGENAgenus to Participate in the Raymond James 2021 Human Health Innovation Conference
LEXINGTON, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that
Read more →AGENAgenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer
LEXINGTON, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infect
Read more →AGENAgenus’ Presentations at ASCO 2021 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373
LEXINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented data
Read more →AGENAgenus to Participate in Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference
LEXINGTON, Mass., June 01, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that
Read more →AGENAgenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts
LEXINGTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced data o
Read more →AGENAgenus to Host Conference Call to Discuss Global Licensing Agreement with Bristol Myers Squibb for Agenus’ Anti-TIGIT Bispecific Antibody Program
LEXINGTON, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that A
Read more →AGENAgenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus Anti-TIGIT Bispecific Antibody Program Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments NEW YORK
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus Anti-TIGIT Bispecific Antibody Program Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments NEW YORK & LEXINGTON, Mass. May 18, 2021 Bristol-Myers Squibb Comp
Read more →AGENAgenus Corporate Update and First Quarter 2021 Financial Report
Balstilimab BLA submitted to FDA for recurrent/metastatic cervical cancer Balstilimab and AGEN2373 data to be presented at ASCO iNKT cell therapy Phase 1 initiated in cancer LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology compa
Read more →AGENAgenus to Present at the 2021 ASCO Annual Meeting
LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that
Read more →AGENAgenus to Provide Corporate Update and First Quarter 2021 Financial Report
LEXINGTON, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that
Read more →AGENAgenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Submission has been made for review under the accelerated approval pathway LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuv
Read more →AGENAgenus Doses First Cancer Patient with iNKT Cell Therapy
LEXINGTON, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced
Read more →AGENAgenus to Participate in Webcast Hosted by William Blair on AGEN1181 and Balstilimab AACR Presentations
LEXINGTON, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that
Read more →AGENAgenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
Completion of balstilimab BLA filing on target for 1H 2021 New clinical data for AGEN1181 to be presented at AACR TIGIT bispecific AGEN1777 IND to be filed in 2Q 2021 iNKT cell therapy cancer trials to commence in 1H 2021 LEXINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) --
Read more →AGENAgenus to Present New Clinical Data on AGEN1181 at AACR 2021
Clinical benefit in previously unresponsive tumors, including CRC, ovarian, and endometrial Confirmed responses in cold tumors as characterized by MSS No neuroendocrine toxicities or hypophysitis Registrational trials planned to commence in 2021 LEXINGTON, Mass., March 10, 20
Read more →AGENAgenus to Provide Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
LEXINGTON, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it w
Read more →AGENAgenus Announces Agenus Insights - Virtual R&D Miniseries
Season 1 Episode 1 (S1E1) on “Optimally Targeting TIGIT” LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate i
Read more →AGENAgenus Announces New Responses for AGEN1181
6 total confirmed objective clinical responses in colon, ovarian, and endometrial cancers No complement-mediated toxicities reported LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoi
Read more →AGENAgenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19
3 out of 4 intubated patients were discharged after treatment 2 out of 4 patients were extubated within 24 hours of dosing LEXINGTON, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibod
Read more →AGENAgenus Enters into Clinical Collaboration with Nelum for Zalifrelimab Combination
LEXINGTON, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced
Read more →AGENAgenus to Participate in B. Riley Securities' Oncology Investor Conference
LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced
Read more →AGENAgenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab
LEXINGTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today ann
Read more →AGENAgenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference
LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced
Read more →AGENAgenus to Participate in Fireside Chat at the Jefferies 2020 Virtual London Healthcare Conference
LEXINGTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced
Read more →AGENAgenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data
LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced
Read more →AGENAgenus and Dr. Steven O’Day to Participate in Panels at the Virtual SITC 2020 Immuno-Oncology Event Hosted by B. Riley
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced
Read more →AGENAgenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020
AGEN1181: New clinical responses and intratumoral Treg depletion AGEN1777 (TIGIT) is Fc enhanced for optimized immune performance & broader benefit AGEN2373 (anti-CD137): Clinical benefit with no liver toxicity Allogeneic iNKTs: Potent tumor cell killing and tumor microenviron
Read more →AGENAgenus Doses First COVID-19 Patient with iNKT Cell Therapy
Allogeneic (off the shelf) iNKT cell therapy targets patients with moderate to severe COVID-19 iNKT cells designed to clear SARS-CoV-2 virus while reducing harmful inflammation LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology co
Read more →AGENAgenus R&D Update & Third Quarter Financial Report
Balstilimab rolling BLA filing and FDA review underway COVID-19 trial open with patients in screening for iNKT Cell Therapy New data and clinical responses with AGEN1181 to be presented at SITC on NOV11 LEXINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: A
Read more →AGENAgenus to Report Third Quarter Earnings
LEXINGTON, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it
Read more →AGENAgenus to Present on Seven Novel Programs at SITC 2020
Clinical Responses: AGEN1181 (Fc-enhanced anti-CTLA-4) +/- balstilimab Clinical Data: Zalifrelimab efficacy in refractory rare tumors Clinical & Preclinical Data: AGEN 2373 (anti-CD137) Phase 2 Data: Optimizing treatment with balstilimab +/- zalifrelimab Cell Therapy with All
Read more →AGENSusan Hirsch Joins Agenus Board of Directors
Susan Hirsch Joins Agenus Board of Directors Mass., October 13, 2020 /GLOBE NEWSWIRE/ Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers
Read more →AGENAgenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer
LEXINGTON, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced the ini
Read more →AGENAgenus Presents Results from Two Large Cervical Cancer Trials at ESMO
160 patient balstilimab (PD-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in PD-L1 positive patients 155 patient balstilimab (PD-1) + zalifrelimab (CTLA-4) combination trial achieves response rates of 22% in all patients and 27% in PD-L1 pos
Read more →AGENAgenus to Participate in Webcast Hosted by William Blair on ESMO2020 Results and Novel Pipeline
LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced t
Read more →AGENPaul Clark Joins Agenus Board of Directors
Paul Clark Joins Agenus Board of Directors LEXINGTON, Mass., August 31, 2020 /PRNewswire/ Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to ca
Read more →AGENAgenus Provides R&D Update & Second Quarter Financial Report Dr. Chuck Drake & Dr. Bree Wilky to discuss AGEN1181 & zalifrelimab - new responses AGEN2373 achieves durable SDs in early Ph1; balstilimab combos to start Zal
Agenus Provides R&D Update & Second Quarter Financial Report LEXINGTON, Mass., August 6, 2020 /PRNewswire/ Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immu
Read more →AGENAgenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals Lexington, Mass.
Agenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals Lexington, Mass., July 28, 2020 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to cancers, today announced the
Read more →AGENAgenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China Agenus to receive $35M upfront with $100M in milestones plus royalties Betta receives exclusive license of
Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China LEXINGTON, Mass., June 22, 2020 /PRNewswire/ Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate
Read more →AGENAgenus First Quarter Results and Update - AGEN1181 (nextgen CTLA-4) +/- balstilimab (anti-PD-1) shows benefit in 70% of patients in Phase 1 - Balstilimab + Zalifrelimab (anti-CTLA-4) achieve 26% response rates in a cohor
Agenus First Quarter Results and Update - AGEN1181 (nextgen CTLA-4) +/- balstilimab (anti-PD-1) shows benefit in 70% of patients in Phase 1 - Balstilimab + Zalifrelimab (anti-CTLA-4) achieve 26% response rates in a cohort of 55 patients with advanced cervical cancer - Two IN
Read more →AGENAgenus Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update - AGEN1181 +/- balstilimab (anti-PD-1) reveals a complete response and new partial responses in phase 1 clinical trial - Ba
Agenus Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update - AGEN1181 +/- balstilimab (anti-PD-1) reveals a complete response and new partial responses in phase 1 clinical trial - Balstilimab & zalifrelimab (anti-CTLA-4) demonstrate 26.5%
Read more →AGENAgenus Announces the Appointment of Dr. Jennifer Buell to the position of President and
Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO LEXINGTON, Mass., January 9, 2020 /PRNewswire/ Agenus Inc. (NASDAQ: AGEN), an Immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, is pl
Read more →AGENAgenus Provides Corporate Update with Third Quarter 2019 Financial Results - PD-1 plus CTLA-4 cervical trial completes planned accrual & planned interim analysis - PD-1 cervical trial on track to complete accrual & plann
Agenus Provides Corporate Update with Third Quarter 2019 Financial Results - PD-1 plus CTLA-4 cervical trial completes planned accrual & planned interim analysis - PD-1 cervical trial on track to complete accrual & planned interim analysis by year-end - Four novel I-O antibodi
Read more →AGENAgenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update Enrollment of CTLA-4 & PD-1 trials on track; data expected 2H2019 Second generation CTLA-4 advances in clinic; data expected 2H2019 Launc
Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update LEXINGTON, Mass., Aug 8, 2019 /PRNewswire/ Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vacci
Read more →AGENAgenus Reports First Quarter 2019 Financial Results and Provides Corporate Update - Gilead partnership yields $150M & first milestone of $7.5M - Exceeding enrollment targets in BLA path CTLA-4 & PD-1 trials - Second gene
Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update - Gilead partnership yields $150M & first milestone of $7.5M - Exceeding enrollment targets in BLA path CTLA-4 & PD-1 trials - Second generation CTLA-4 in the clinic; combos and data planned in 2
Read more →AGENAgenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update - Gilead collaboration results in cash infusion of $150M; first milestone payment of $7.5M triggered - CTLA-4 & PD-1 trials
Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update - Gilead collaboration results in cash infusion of $150M; first milestone payment of $7.5M triggered - CTLA-4 & PD-1 trials are accruing for planned BLA filing as early as 2020 - N
Read more →AGENImpact of Tokens on AGEN2034 economics - Illustrative US Net Sales of AGEN2034 - Illustrative Year Total ($ Millions) Distribution to Token Holders ($ Millions) Retained by Agenus ($ Millions) 2021 100.00 70.00 30.00 202
What is a Biotech Electronic Security Token (B.E.S.T)? B.E.S.T. will be built upon blockchain technology, B.E.S.T. is NOT a cryptocurrency. The first B.E.S.T is offered for a late stage product, AGEN2034, a PD-1 antibody. All PD-1 molecules that entered late stage development ha
Read more →AGENAgenus Closes $150 Million Immuno-Oncology Transaction with Gilead Lexington, Mass.
Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead Lexington, Mass., January 24, 2019 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies1, today announced the closi
Read more →AGENGilead Contacts: Sung Lee, Investors (650) 524-7792 Nathan Kaiser, Media (650) 522-1853 Agenus Contact: Jennifer Buell, PhD, Investors 781-674-4420 Jennifer.Buell@agenusbio.com Olivia Mullane, Media 212-715-1597 GILEAD A
GILEAD AND AGENUS ENTER INTO COLLABORATION TO DEVELOP IMMUNO-ONCOLOGY THERAPIES Agenus Webcast and Conference Call Scheduled for Today at 8:30a.m.ET Foster City, Calif. and Lexington, Mass., December 20, 2018 Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN)
Read more →AGENAgenus Reports Third Quarter 2018 Financial Results and Provides Corporate Update - 130 patients treated with Agenus PD-1 & CTLA-4; clinical benefit 63% treated - Recent FDA meeting confirms path to BLA filing; targeted
Agenus Reports Third Quarter 2018 Financial Results and Provides Corporate Update - 130 patients treated with Agenus' PD-1 & CTLA-4; clinical benefit >63% treated - Recent FDA meeting confirms path to BLA filing; targeted for 2020 - Next-Gen CTLA-4 IND filed; four INDs filed y
Read more →AGENAgenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update - Cash milestones earned from Merck & Incyte - Three INDs filed and 3 more to be filed during 2018 - CTLA-4 & PD-1 trials treated more th
Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update - Cash milestones earned from Merck & Incyte - Three INDs filed and 3 more to be filed during 2018 - CTLA-4 & PD-1 trials treated more than 115 patients; clinical benefit confirmed LEXINGTON, M
Read more →AGENAgenus Reports First Quarter 2018 Financial Results and Provides Corporate Update Agenus to host conference call and webcast today at 11am
Agenus Reports First Quarter 2018 Financial Results and Provides Corporate Update Agenus to host conference call and webcast today at 11am ET LEXINGTON, Mass., May 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune che
Read more →AGENAgenus Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update LEXINGTON, MA, March 15 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of im
Agenus Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update LEXINGTON, MA, March 15, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided
Read more →AGENAgenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners LEXINGTON, MA
Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners LEXINGTON, MA, January 8, 2018 /PRNewswire/ Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $23
Read more →AGENAgenus Receives License Fee of $4 Million USD from Merck Entitled up to an additional $99 million USD in success milestones plus royalties on sales
Agenus Receives License Fee of $4 Million USD from Merck Entitled up to an additional $99 million USD in success milestones plus royalties on sales LEXINGTON, Mass., November 15, 2017 /PRNewswire/ Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of
Read more →AGENAgenus Reports Second Quarter 2017 Financial Results and Provides Corporate Update Earnings Conference call at 11am ET today
Agenus Reports Second Quarter 2017 Financial Results and Provides Corporate Update Earnings Conference call at 11am ET today LEXINGTON, Mass., Aug. 3, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodi
Read more →AGENAgenus Reports First Quarter 2017 Financial Results and Provides Corporate Update Substantial advances in clinical programs Update on novel differentiated preclinical programs, including cell therapy Corporate transactio
Agenus Reports First Quarter 2017 Financial Results and Provides Corporate Update Substantial advances in clinical programs Update on novel differentiated preclinical programs, including cell therapy Corporate transaction resulting in $80M cash infusion and ~$70M in projected
Read more →AGENPhase 1/2 Clinical Trial of Agenus anti-PD-1 Antibody Begins First patient dosed; combination trials with anti-PD-1 plus anti-CTLA-4 antibodies planned by year-end
Phase 1/2 Clinical Trial of Agenus' anti-PD-1 Antibody Begins First patient dosed; combination trials with anti-PD-1 plus anti-CTLA-4 antibodies planned by year-end LEXINGTON, Mass., April 20, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company wit
Read more →AGENAgenus Restructures Business to Sharpen Focus on Clinical Development of Cancer Therapies - Will Host Conference Call at 9am ET Today
Agenus Restructures Business to Sharpen Focus on Clinical Development of Cancer Therapies - Will Host Conference Call at 9am ET Today - LEXINGTON, Mass., March 30, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a clinical stage pipeline of immu
Read more →AGENAgenus Reports Fourth Quarter and Full Year 2016 Results - Will Host Update Conference Call at 11am ET Today
Agenus Reports Fourth Quarter and Full Year 2016 Results - Will Host Update Conference Call at 11am ET Today - LEXINGTON, Mass., March 9, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer
Read more →AGENIncyte and Agenus Amend Collaboration Agreement Incyte secures global clinical development and commercialization responsibilities for GITR and OX40 programs, converting both from profit-sharing to r
Incyte and Agenus Amend Collaboration Agreement Incyte secures global clinical development and commercialization responsibilities for GITR and OX40 programs, converting both from profit-sharing to royalty-bearing arrangements Agenus to receive $80 million from Incyte: $60 mill
Read more →AGENAgenus announces collaboration with the National Cancer Institute to evaluate the combination of Pembrolizumab (Keytruda , Merck & Co., Inc.) with Prophage (Agenus Inc.) autologous vaccine
Agenus announces collaboration with the National Cancer Institute to evaluate the combination of Pembrolizumab (Keytruda , Merck & Co., Inc.) with Prophage (Agenus Inc.) autologous vaccine LEXINGTON, Mass., Jan. 17, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-onco
Read more →AGENAgenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors - Third antibody from Agenus to enter the clinic this year
Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors - Third antibody from Agenus to enter the clinic this year - LEXINGTON, Mass., Nov. 30, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno
Read more →AGENAgenus Reports Third Quarter Financial Results and Recent Highlights Company to host conference call at 11:00 a.m. ET today
Agenus Reports Third Quarter Financial Results and Recent Highlights Company to host conference call at 11:00 a.m. ET today LEXINGTON, Mass., Oct. 27, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint i
Read more →AGENAgenus Reports Second Quarter 2016 Financial Results and Operational Progress Company to host conference call at 11:00 a.m. ET today LEXINGTON, Mass.--(BUSINESS WIRE)
Reports Second Quarter 2016 Financial Results and Operational Progress to host conference call at 11:00 a.m. ET today LEXINGTON, Mass.--(BUSINESS WIRE)--July 28, 2016--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inh
Read more →AGENAgenus Appoints Jean-Marie Cuillerot, M.D. as Vice President and Global Head of Clinical Development - Previously with Merck Serono and Bristol Myers Squibb - LEXINGTON, Mass.--(BUSINESS WIRE)
Appoints Jean-Marie Cuillerot, M.D. as Vice President and Global Head of Clinical Development Previously with Merck Serono and Bristol Myers Squibb - LEXINGTON, Mass.--(BUSINESS WIRE)--July 6, 2016--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antib
Read more →AGENAgenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors LEXINGTON, Mass.--(BUSINESS WIRE)
Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors LEXINGTON, Mass.--(BUSINESS WIRE)--June 22, 2016--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inh
Read more →AGENAgenus Announces Lead Product Candidate Selection in its Collaboration with Merck Received First Milestone Payment of $2 Million LEXINGTON, Mass.--(BUSINESS WIRE)
Announces Lead Product Candidate Selection in its Collaboration with First Milestone Payment of $2 Million LEXINGTON, Mass.--(BUSINESS WIRE)--June 9, 2016--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other c
Read more →AGENAgenus Reports First Quarter 2016 Financial Results and Operational Progress Company to host conference call at 11am ET today LEXINGTON, Mass.--(BUSINESS WIRE)
Reports First Quarter 2016 Financial Results and Operational Progress to host conference call at 11am ET today LEXINGTON, Mass.--(BUSINESS WIRE)--April 28, 2016--Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today
Read more →AGENAgenus Commences Phase 1 Clinical Trial of its CTLA-4 Checkpoint Antibody to Treat Solid Tumors LEXINGTON, Mass.--(BUSINESS WIRE)
Commences Phase 1 Clinical Trial of its CTLA-4 Checkpoint Antibody to LEXINGTON, Mass.--(BUSINESS WIRE)--April 27, 2016--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today announced that the first patient has been
Read more →AGENAgenus Reports Fourth Quarter and Full Year 2015 Financial and Operational Results and Recent Highlights Company to host conference call at 11am ET today LEXINGTON, Mass.--(BUSINESS WIRE)
Reports Fourth Quarter and Full Year 2015 Financial and Operational Results and Recent Highlights to host conference call at 11am ET today LEXINGTON, Mass.--(BUSINESS WIRE)--March 3, 2016--Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing checkpoint modulator
Read more →AGENAgenus Announces Clearance of Investigational New Drug Applications by the FDA for anti-CTLA-4 and anti-GITR Antibodies Clinical studies for both checkpoint modulator antibodies allowed to commence LEXINGTON, Mass.--(BUS
Announces Clearance of Investigational New Drug Applications by the FDA for anti-CTLA-4 and anti-GITR Antibodies studies for both checkpoint modulator antibodies allowed to commence LEXINGTON, Mass.--(BUSINESS WIRE)--January 21, 2016--Agenus Inc. (NASDAQ: AGEN), an immuno-onc
Read more →AGENAgenus Completes XOMA Antibody Manufacturing Pilot Plant Acquisition
Agenus Completes XOMA Antibody Manufacturing Pilot Plant Acquisition LEXINGTON, Mass January 4, 2016 - Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing innovative treatments for patients with cancer, announced today that it has completed the previously announced
Read more →AGENAgenus Acquires PhosImmune with a Novel Class of Cancer Neoantigens Offers the potential for rapid advancement of clinical programs and creation of new partnerships Novel class of cancer neoantigens further differentiate
Agenus Acquires PhosImmune with a Novel Class of Cancer Neoantigens Offers the potential for rapid advancement of clinical programs and creation of new partnerships Novel class of cancer neoantigens further differentiate AutoSynVax vaccine platform LEXINGTON, Mass December 23,
Read more →AGENForward-Looking Statements This presentation contains forward-looking statements, including statements regarding the Company's pending acquisition of XOMA Corporation's antibody pilot plant manufacturing facility and cap
Agenus R&D Day November 19, 2015 New York, NY Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding the Company's pending acquisition of XOMA Corporation's antibody pilot plant manufacturing facility and c
Read more →AGENAgenus to Acquire Antibody Manufacturing Capability, Expands Antibody Discovery and adds Cell Line Development Capabilities with Three Separate Transactions To acquire biologics manufacturing facility and capabilities fr
Acquire Antibody Manufacturing Capability, Expands Antibody Discovery and adds Cell Line Development Capabilities with Three Separate acquire biologics manufacturing facility and capabilities from XOMA rights to Selexis cell line development technology an exclusive license to
Read more →AGENAgenus Reports Third Quarter 2015 Financial Results Corporate Update Conference Call at 11 am ET Today LEXINGTON, Mass.--(BUSINESS WIRE)
Reports Third Quarter 2015 Financial Results Update Conference Call at 11 am ET Today LEXINGTON, Mass.--(BUSINESS WIRE)--October 27, 2015--Agenus Inc. (NASDAQ:AGEN), an immunology company discovering and developing innovative treatments for cancers and other diseases, today a
Read more →AGENAgenus Inc. Completes $115 Million Non-Dilutive Royalty Transaction with Oberland Capital LEXINGTON, MA
Agenus Inc. Completes $115 Million Non-Dilutive Royalty Transaction with Oberland Capital LEXINGTON, MA September 9, 2015 Agenus Inc. (NASDAQ: AGEN), an immunology company discovering and developing innovative treatments for cancers and other diseases, today announced a $115 mi
Read more →AGENGSK's Malaria Vaccine Containing Agenus' QS-21 Stimulon Receives Positive Opinion from European Regulators for Prevention of Malaria in Young Children in Sub-Saharan Africa LEXINGTON, Mass.--(BUSINESS WIRE)
Malaria Vaccine Containing Agenus' QS-21 Stimulon Receives Positive Opinion from European Regulators for Prevention of Malaria in Young Children in Sub-Saharan Africa LEXINGTON, Mass.--(BUSINESS WIRE)--July 24, 2015--Agenus Inc. (NASDAQ:AGEN), an immunology company discoverin
Read more →AGENAgenus Reports Second Quarter 2015 Financial Results Corporate Update Conference Call at 11 am ET Today LEXINGTON, Mass.--(BUSINESS WIRE)
Reports Second Quarter 2015 Financial Results Update Conference Call at 11 am ET Today LEXINGTON, Mass.--(BUSINESS WIRE)--July 23, 2015--Agenus Inc. (NASDAQ:AGEN), an immunology company discovering and developing innovative treatments for cancers and other diseases, today ann
Read more →AGENAgenus Acquires Novel Antibodies to Immuno-oncology Target CEACAM1 Target Expressed on Lymphocytes and Tumors Offers Unique Advantages for Unlocking the Immune Response to Fight Cancer LEXINGTON, Mass.--(BUSINESS WIRE)
Acquires Novel Antibodies to Immuno-oncology Target CEACAM1 Expressed on Lymphocytes and Tumors Offers Unique Advantages for Unlocking the Immune Response to Fight Cancer LEXINGTON, Mass.--(BUSINESS WIRE)--July 20, 2015--Agenus Inc. (NASDAQ: AGEN), an immunology company devel
Read more →AGENAgenus Appoints C. Evan Ballantyne as Chief Financial Officer LEXINGTON, Mass.--(BUSINESS WIRE)
Appoints C. Evan Ballantyne as Chief Financial Officer LEXINGTON, Mass.--(BUSINESS WIRE)--June 17, 2015--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced the appointment of C. Evan Ballantyne as
Read more →AGENMerck Extends Immuno-Oncology Collaboration with Agenus Collaboration involves two proprietary Merck targets LEXINGTON, Mass.--(BUSINESS WIRE)
Extends Immuno-Oncology Collaboration with Agenus involves two proprietary Merck targets LEXINGTON, Mass.--(BUSINESS WIRE)--June 3, 2015--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, announced today that Me
Read more →AGENUpdated Phase 2 Data of Prophage In Newly Diagnosed GBM Presented at ASCO Show Improvement in Median Progression Free Survival and Overall Survival Independently of Prognostic Markers, Compared with Historical Expectatio
Phase 2 Data of Prophage In Newly Diagnosed GBM Presented at ASCO Show Improvement in Median Progression Free Survival and Overall Survival Independently of Prognostic Markers, Compared with Historical significant improvements seen in patients with less elevated PD-L1 express
Read more →AGENAgenus Announces Closing of Public Offering and Exercise in Full of Underwriters Option to Purchase Additional Shares of Common Stock
Agenus Announces Closing of Public Offering and Exercise in Full of Underwriters Option to Purchase Additional Shares of Common Stock LEXINGTON, Mass May 27, 2015 Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases,
Read more →AGENAgenus Announces Proposed Public Offering of Common Stock
Agenus Announces Proposed Public Offering of Common Stock LEXINGTON, Mass May 20, 2015 Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing immune-oncology checkpoint modulators (CPMs), heat shock protein peptide-based vaccines and immune adjuvants, today announced t
Read more →AGENAgenus R&D Day May 14th 2015 Driving the immune a system to fight cancer and infectious disease Note Regarding Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking state
Agenus R&D Day May 14th 2015 immune a system to fight cancer and infectious disease Note Regarding Forward-Looking Statements presentation contains forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including the factors descri
Read more →AGENNEJM Publishes Study Showing GSK's Shingles Vaccine Containing Agenus' QS-21 Stimulon Adjuvant Provides over 97% Protection in People Over the Age of 50 Data simultaneously presented at ECCMID HZ/su vaccine achieves near
Publishes Study Showing GSK's Shingles Vaccine Containing Agenus' QS-21 Stimulon Adjuvant Provides over 97% Protection in People Over the Age simultaneously presented at ECCMID vaccine achieves nearly 98% protection in people 70 or older marks the second successful Phase 3 cl
Read more →AGENGSK's Malaria Vaccine Phase 3 Study Containing Agenus' QS-21 Published in The Lancet Final study results show significant reduction in malaria cases EMA currently reviewing the regulatory application LEXINGTON, Mass.--(B
Malaria Vaccine Phase 3 Study Containing Agenus' QS-21 Published in The study results show significant reduction in malaria cases currently reviewing the regulatory application LEXINGTON, Mass.--(BUSINESS WIRE)--April 24, 2015--Agenus Inc. (NASDAQ: AGEN), an immunology compan
Read more →AGENAgenus Reports First Quarter 2015 Financial Results Corporate Update Conference Call at 11 am ET Today Agenus to Host R&D Day in New York, NY on May 14 LEXINGTON, Mass.--(BUSINESS WIRE)
Reports First Quarter 2015 Financial Results Update Conference Call at 11 am ET Today to Host R&D Day in New York, NY on May 14 LEXINGTON, Mass.--(BUSINESS WIRE)--April 23, 2015--Agenus Inc. (NASDAQ:AGEN), an immunotherapy company developing immune-oncology checkpoint modula
Read more →AGENAGENUS ACQUIRES CELEXION ASSETS AND EXPANDS ITS ANTIBODY DISCOVERY PLATFORM SECANT yeast display technology to provide speed and cost advantages Combination with Agenus' mammalian Retrocyte Display TM technology to resul
AGENUS ACQUIRES CELEXION ASSETS AND EXPANDS ITS ANTIBODY DISCOVERY PLATFORM LEXINGTON, Mass. -April 8, 2015 - Agenus Inc. (NASDAQ: AGEN) an immunology company developing innovative treatments for cancers and other diseases, today announced the acquisition of key antibody assets
Read more →AGENAgenus Reports Fourth Quarter and Full Year 2014 Financial Results Agenus to host conference call at 11 a.m. ET today LEXINGTON, Mass.--(BUSINESS WIRE)
Reports Fourth Quarter and Full Year 2014 Financial Results to host conference call at 11 a.m. ET today LEXINGTON, Mass.--(BUSINESS WIRE)--February 26, 2015--Agenus Inc. (NASDAQ:AGEN), an immunology company developing novel therapeutic approaches based on checkpoint modulator
Read more →AGENIncyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies Alliance to initially focus on four checkpoint modulator programs directed at GITR, OX40, TIM-3 and LAG-3 Incyt
Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies WILMINGTON, DE and LEXINGTON, MA January 9, 2015 Incyte Corporation (Nasdaq: INCY) and Agenus Inc. (Nasdaq: AGEN) today announced a global license, development and commercialization agreemen
Read more →AGENAgenus Reports Third Quarter 2014 Financial Results Agenus to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--(BUSINESS WIRE)
Reports Third Quarter 2014 Financial Results to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--(BUSINESS WIRE)--October 31, 2014--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a development pipeline of checkpoint modulators (CPMs), heat sho
Read more →AGENAgenus Reports Second Quarter 2014 Financial Results Agenus to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--(BUSINESS WIRE)
Reports Second Quarter 2014 Financial Results to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--(BUSINESS WIRE)--July 24, 2014--Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock prote
Read more →AGENFirst Vaccine Candidate for Malaria is Accepted for EU Regulatory Review GSK's RTS,S is the world's first malaria vaccine candidate to undergo regulatory review Agenus' QS-21 Stimulon is a component of RTS,S and in 16 ad
Vaccine Candidate for Malaria is Accepted for EU Regulatory Review RTS,S is the world's first malaria vaccine candidate to undergo a component of RTS,S and in 16 additional vaccine candidates undergoing patient studies triggered regulatory milestone payment; Agenus entitled t
Read more →AGENAgenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis Median Overall Survival Nearly Double than Expected with Standard of Care Alone LEXINGTON, Mass.--(BUSINESS WIRE)
Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Overall Survival Nearly Double than Expected with Standard of Care LEXINGTON, Mass.--(BUSINESS WIRE)--July 1, 2014--Agenus Inc. (NASDAQ: AGEN), announced final results from a single-arm, multi-institutional, o
Read more →AGENAgenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation Phase 2 trial in patients with genital herpes shows correlation between viral load reduction and CD8 T cell activation, a
Reduction in Viral Burden after HerpV Generated Immune Activation trial in patients with genital herpes shows correlation between viral load reduction and CD8 T cell activation, an important clinical shows booster shot demonstrates sustainable, long-term effect LEXINGTON, Mas
Read more →AGENAgenus Selected for Inclusion in the Russell 3000 Index and Global Index LEXINGTON, Mass.--(BUSINESS WIRE)
Selected for Inclusion in the Russell 3000 Index and Global Index LEXINGTON, Mass.--(BUSINESS WIRE)--June 16, 2014--Agenus, Inc. (NASDAQ:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, announ
Read more →AGENAgenus Reports First Quarter 2014 Financial Results Agenus to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--(BUSINESS WIRE)
Reports First Quarter 2014 Financial Results to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--(BUSINESS WIRE)--May 8, 2014--Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein
Read more →AGENAgenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-Based Cancer Immunotherapies Agenus is eligible to receive ~$100 million in milestone payments as well as royalties on worldwi
Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-Based Cancer Immunotherapies is eligible to receive ~$100 million in milestone payments as well as royalties on worldwide product sales LEXINGTON, Mass.--(BUSINESS WIRE)--April 28, 2014--Ag
Read more →AGENUpdate on GSK'S MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell Lung Cancer LEXINGTON, Mass.--(BUSINESS WIRE)
GSK'S MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell LEXINGTON, Mass.--(BUSINESS WIRE)--April 2, 2014--Agenus Inc. (Nasdaq: AGEN) today announced that GlaxoSmithKline's (NYSE: GSK) MAGRITi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3ii ca
Read more →AGENGSK's MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell Lung Cancer Misses First Co-Primary Endpoints GSK to continue study until third co-primary endpoint is assessed LEXINGTON, Mass.--(BUSINESS WIRE)
MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell Lung Cancer Misses First Co-Primary Endpoints continue study until third co-primary endpoint is assessed LEXINGTON, Mass.--(BUSINESS WIRE)--March 20, 2014--Agenus Inc. (Nasdaq: AGEN) today announced that GlaxoSm
Read more →AGENAgenus Reports Fourth Quarter and Full Year 2013 Financial Results Agenus to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--(BUSINESS WIRE)
Reports Fourth Quarter and Full Year 2013 Financial Results to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--(BUSINESS WIRE)--March 5, 2014--Agenus Inc. (NASDAQ: AGEN), a biopharmaceutical company developing a portfolio of immuno-oncology candidates, in
Read more →AGENAgenus Completes Acquisition of 4-Antibody Agenus gains powerful platform for rapid discovery and optimization of fully-human antibodies against a wide array of molecular targets LEXINGTON, Mass.--(BUSINESS WIRE)
Completes Acquisition of 4-Antibody gains powerful platform for rapid discovery and optimization of fully-human antibodies against a wide array of molecular targets LEXINGTON, Mass.--(BUSINESS WIRE)--February 13, 2014--Agenus Inc. (Nasdaq: AGEN), a biopharmaceutical company d
Read more →AGENAgenus Reports Second Quarter 2013 Financial Results
LEXINGTON, Mass., July 25, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its financial results and business highlights for the second quarter en
Read more →AGENAgenus to Report Second Quarter 2013 Financial Results on July 25, 2013; Conference Call to Follow
LEXINGTON, Mass., July 18, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its second quarter 2013 financial results before the market opens on July 25, 2013. Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To access the li
Read more →AGENAgenus to Present at the JMP Securities Annual Healthcare Conference
LEXINGTON, Mass., July 2, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the JMP Securities 8th Annual Healthcare Conference, which will be held at
Read more →AGENAgenus to Webcast Annual Shareholders' Meeting
LEXINGTON, Mass., June 10, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) invites investors and the general public to its Annual Shareholders' Meeting at 5:00 p.m. ET on Wednesday, June 12, 2013. The meeting will be held at the company's headquarters located at 3 Forbes Road,
Read more →AGENAgenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine With Avastin in Treatment of Brain Tumors
LEXINGTON, Mass., May 22, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced enrollment has started for a large, randomized Phase 2 study of Prophage G-200 (Heat Shock Protein Peptide Complex-96 or HSPPC-96) vaccine in combination with bevacizumab (Avastin ) for t
Read more →AGENAgenus Reports First Quarter 2013 Financial Results
LEXINGTON, Mass., April 24, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its financial results and business highlights for the first quarter en
Read more →AGENAgenus to Report First Quarter 2013 Financial Results on April 24, 2013; Conference Call to Follow
LEXINGTON, Mass., April 18, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its first quarter 2013 financial results before the market opens on April 24, 2013. Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To access the l
Read more →AGENAgenus Eliminates Its $39 Million Senior Notes and Completes $10 Million of New Debt Financing
LEXINGTON, Mass., April 16, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a leading developer of therapeutic vaccines for cancer and infectious diseases, reported today that it has retired its outstanding $39 million 8.00% senior secured convertible notes issued in 2006 due
Read more →AGENAgenus' Brain Cancer Vaccine Results to be Presented at Plenary Session of the 81st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting
LEXINGTON, Mass., April 10, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today that Orin Bloch, MD, Clinical Instructor, Department of Neurological Surgery, University of California San Francisco (UCSF), will present an abstract that reports on outcomes with HSPPC-
Read more →AGENAgenus to Present at the ROTH Annual Conference
LEXINGTON, Mass., March 14, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the 25th Annual ROTH Conference, which will be held at the Ritz Carlton,
Read more →AGENAgenus Reports Fourth Quarter and Year End 2012 Financial Results
LEXINGTON, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its financial results and business highlights for the fourth quarter an
Read more →AGENAgenus' HerpV Phase 2 Study to Treat Genital Herpes Completes Enrollment
HerpV is clinically the most advanced therapeutic vaccine for the treatment of genital herpes HerpV contains Agenus' QS-21 Stimulon * adjuvant currently being studied in 17 other clinical programs LEXINGTON, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a
Read more →AGENAgenus to Present at Cowen and Company Annual Healthcare Conference
LEXINGTON, Mass., Feb. 26, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the Cowen and Company 33rd Annual Healthcare Conference, which will be hel
Read more →AGENAgenus to Report Fourth Quarter and Year End 2012 Financial Results on February 28, 2013; Conference Call to Follow
LEXINGTON, Mass., Feb. 21, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its fourth quarter and year ended December 31, 2012 financial results before the market opens on February 28, 2013. Agenus executives will host a conference call at 11:00 a.m. Eastern Time
Read more →AGENAgenus to Present at BIO CEO & Investor Conference
LEXINGTON, Mass., Feb. 6, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the 15th Annual BIO CEO & Investor Conference, which will be held at the Wa
Read more →AGENAgenus to Present at OneMedForum San Francisco 2013
LEXINGTON, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the 6th Annual OneMedForum San Francisco 2013, which will be held at the Si
Read more →AGENAgenus to Present at Windhover's Therapeutic Area Partnerships Conference
Agenus' HerpV Named One of the "2012 Top Programs to Watch" by Windhover LEXINGTON, Mass., Nov. 26, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that Cristina Musselli, MD, Ph.D, Senio
Read more →AGENAgenus Reports Third Quarter 2012 Financial Results
LEXINGTON, Mass., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its financial results and business highlights for the third quarter end
Read more →AGENAgenus Commences Phase 2 Study of HerpV Vaccine for the Treatment of Genital Herpes
HerpV is the most clinically advanced therapeutic vaccine candidate for the treatment of genital herpes Contains Agenus' QS-21 Stimulon adjuvant currently being studied in 17 clinical programs LEXINGTON, Mass., Oct. 23, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a deve
Read more →AGENAgenus to Report 3rd Quarter Financial Results on October 25, 2012; Conference Call to Follow
LEXINGTON, Mass., Oct. 18, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its third quarter financial results before the market opens on October 25, 2012. Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To access the live
Read more →AGENAgenus to Present at 3rd Annual Cancer Immunotherapy Conference
LEXINGTON, Mass., Sept. 28, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of vaccines for cancer and infectious diseases, today announced that the company will be presenting at the 3rd Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference taking place
Read more →AGENAgenus to Present at the NewsMakers in the Biotech Industry Conference and the Rodman & Renshaw Global Investment Conference
LEXINGTON, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of vaccines for cancer and infectious diseases, today announced that Garo Armen, Ph.D, chairman and CEO of Agenus, will present a corporate overview at two upcoming conferences. They includ
Read more →AGENAgenus Announces Publication of Key Data Showing Antitumor Activity of Prophage Vaccine (HSPPC-96) in Clinical Cancer Research
LEXINGTON, Mass., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology-based treatments for cancers and infectious diseases, today announced the publication of key clinical data from a Phase 1 trial of a Prophage
Read more →AGENAgenus Reports Second Quarter 2012 Financial Results
LEXINGTON, Mass., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology-based treatments for cancers and infectious diseases, today reported its financial results and business and clinical highlights for the second
Read more →AGENAgenus to Report 2nd Quarter Financial Results on August 2, 2012; Conference Call to Follow
LEXINGTON, Mass., July 26, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its second quarter financial results before the market opens on August 2, 2012. Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To access the live c
Read more →AGENAgenus to Join Russell 3000 Index, Global Index, and MicroCap Index
LEXINGTON, Mass., June 18, 2012 (GLOBE NEWSWIRE) -- Agenus, Inc. (Nasdaq:AGEN), a biotechnology company working to develop treatments for cancers and infectious diseases, today announced that it is set to join the broad-market Russell 3000 Index, Russell Global Index, and Russell
Read more →AGENAgenus to Webcast 2012 Annual Shareholders Meeting
LEXINGTON, Mass., June 1, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) invites investors and the general public to its 2012 Annual Shareholders Meeting at 5:00 p.m. ET on Wednesday, June 13th. The meeting will be held at the company's headquarters at 3 Forbes Road, Lexingto
Read more →AGENAgenus Reports First Quarter 2012 Financial Results and Corporate Updates
LEXINGTON, Mass., April 25, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today its results for the first quarter ended March 31, 2012. The company reported net income attributable to common stockholders of $6.6 million, or $0.29 per share, basic and diluted for the
Read more →AGENAgenus' Brain Cancer Vaccine Phase 2 Study to be Presented at Plenary Session of the 80th American Association of Neurological Surgeons (AANS) Annual Scientific Meeting
LEXINGTON, Mass., April 2, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today that Dr. Andrew Parsa, Professor in Residence, Department of Neurological Surgery, University of California San Francisco (UCSF), will present an abstract entitled, "A Phase 2 multicenter
Read more →AGENAgenus Reports Fourth Quarter and Year End 2011 Financial Results and Corporate Updates
In the First Quarter 2012, Agenus Increased Its Cash Position by Approximately $18 Million Agenus to Host Conference Call Beginning at 11 am ET Today LEXINGTON, Mass., March 5, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today its results for the fourth quarter
Read more →AGENAgenus Expands QS-21 License and Grants Right of First Negotiation to GlaxoSmithKline
Agenus to Receive $9 Million Upfront Agenus to Host a Conference Call at 11 am ET Today LEXINGTON, Mass., March 5, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) announced today that GlaxoSmithKline (GSK) and Agenus have amended the QS-21 license and manufacturing agreement
Read more →AGENAgenus to Present at the 2012 Cowen Health Care Conference
LEXINGTON, Mass., March 1, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the 32nd Annual Cowen and Company Health Care Conference, which will be he
Read more →AGENAgenus to Report Fourth Quarter and Year-End 2011 Financial Results on March 5, 2012; Conference Call to Follow
LEXINGTON, Mass., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its fourth quarter and full-year financial results before the market opens on March 5, 2012. Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To acce
Read more →AGENAgenus to Present at OneMedForum San Francisco 2012
LEXINGTON, Mass., Jan. 4, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the 5th Annual OneMedForum San Francisco 2012, which will be held at the Si
Read more →AGENAgenus and ChemRar Enter Into Agreement in the Area of Personalized Cancer Vaccines
LEXINGTON, Mass. and MOSCOW, Dec. 19, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop treatments for cancers and infectious diseases, and NewVac LLC (a subsidiary of ChemRar High Tech Center and resident of the Skolkovo Innovation Ce
Read more →AGENAgenus Vaccine for Brain Cancer Highlighted at Current State of the Art Session at the Annual Society for Neuro-Oncology (SNO) Meeting
LEXINGTON, Mass., Nov. 16, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today that Dr. Michael Sughrue, incoming Director of the Comprehensive Brain Tumor Center, University of Oklahoma, will give a presentation on Agenus' Prophage Series G-200 (HSPPC-96; vitespen)
Read more →AGENAgenus Reports Third Quarter 2011 Financial Results and Corporate Updates
LEXINGTON, Mass., Oct. 27, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today its results for the third quarter and nine months ended September 30, 2011. The company reported a net loss attributable to common stockholders of $5.7 million, or $0.28 per share, basic
Read more →AGENAgenus to Report Third Quarter Financial Results on October 27, 2011; Conference Call to Follow
LEXINGTON, Mass., Oct. 20, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its third quarter financial results before the market opens on October 27, 2011. Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To access the live
Read more →AGENAgenus to Present at NewsMakers in the Biotech Industry Conference
LEXINGTON, Mass., Oct. 18, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the NewsMakers in the Biotech Industry Conference on Friday, October 21st
Read more →AGENAgenus Compliant With NASDAQ Listing Requirements
LEXINGTON, Mass., Oct. 17, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced that it has received notice from the NASDAQ Listing Qualifications Panel (the "Panel") that the Company has regained compliance with the $1.00 bid price requirement set forth in NASDAQ L
Read more →AGENAgenus Announces Stock Symbol to Revert Back to AGEN
LEXINGTON, Mass., Oct. 11, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEND), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that in response to the Company's request, NASDAQ will remove the fifth character "D" from the Company's stock s
Read more →AGENAgenus to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
LEXINGTON, Mass., Oct. 3, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the second annual Cancer Immunotherapy: A Long-Awaited Reality Conference o
Read more →AGENAgenus Announces Reverse Stock Split
LEXINGTON, Mass., Sept. 30, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that its board of directors has approved a 1-for-6 share consolidation, or reverse stock split, that will become
Read more →AGENAgenus to Present at JMP Securities Healthcare Conference
LEXINGTON, Mass., Sept. 22, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a leading developer of therapeutic vaccines for cancer and infectious diseases, today announced that Dr. Garo Armen, Chairman and CEO, is scheduled to present at the JMP Securities Healthcare Conferen
Read more →AGENAgenus to Present at Rodman & Renshaw Annual Global Investment Conference
LEXINGTON, Mass., Sept. 9, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a leading developer of therapeutic vaccines for cancer and infectious diseases, today announced that Dr. Garo Armen, Chairman and CEO is scheduled to present at the Rodman & Renshaw Annual Global Inves
Read more →AGENAgenus Prices at Market Underwritten Offering of Common Stock
LEXINGTON, Mass., Aug. 11, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a leading developer of therapeutic vaccines for cancer and infectious diseases, today announced the pricing of an at market underwritten offering of 13,725,491 primary shares of its common stock at a p
Read more →AGENAgenus Reports Second Quarter 2011 Financial Results and Corporate Updates
LEXINGTON, Mass., July 28, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today its results for the quarter and six months ended June 30, 2011. The company reported a net loss attributable to common stockholders of $6.0 million, or $0.05 per share, basic and diluted,
Read more →AGENAgenus to Report Second Quarter Financial Results on July 28, 2011; Conference Call to Follow
LEXINGTON, Mass., July 21, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its second quarter financial results before the market opens on July 28, 2011. Agenus executives will host a conference call at 10:00 a.m. Eastern Time that same day. To access the live ca
Read more →AGENAgenus' Herpes Study Results Presented at BIO International Convention Show Robust Immune Response
LEXINGTON, Mass., June 27, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a leading developer of therapeutic vaccines for cancer and infectious diseases, today announced that results from its Phase I study of HerpV for the treatment of genital herpes will be presented by Dr.
Read more →AGENAgenus' QS-21 Stimulon(R) Adjuvant Selected for Biodefense Program
LEXINGTON, Mass., June 14, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) announced today a license agreement with Integrated BioTherapeutics Inc. (IBT) for the use of the QS-21 Stimulon adjuvant in the development of a vaccine against Ebola and Marburg viruses1. Under this a
Read more →AGENAgenus to Webcast 2011 Annual Shareholders Meeting
LEXINGTON, Mass., June 1, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) invites investors and the general public to its 2011 Annual Shareholders Meeting at 5:00 p.m. ET on Wednesday, June 15. The meeting will be held at the company's headquarters at 3 Forbes Road, Lexington,
Read more →AGENAgenus Announces Investor Briefing at the American Society of Clinical Oncology (ASCO) 2011 Chicago Meeting
LEXINGTON, Mass., May 24, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced that it will host an investor/analyst briefing on June 6th from 2-3 p.m. CT (3-4 p.m. ET). The purpose of the briefing is to review the latest clinical data on the Prophage Series G-200 v
Read more →AGENAgenus Reports First Quarter 2011 Financial Results
LEXINGTON, Mass., April 28, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today its results for the first quarter of 2011. The company reported a net loss attributable to common stockholders of $6.2 million, or $0.05 per share, basic and diluted, for the first quart
Read more →AGENAgenus to Report First Quarter Financial Results on April 28, 2011; Conference Call to Follow
LEXINGTON, Mass., April 21, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its first quarter financial results before the market opens on April 28, 2011. Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To access the live c
Read more →AGENAgenus Receives NASDAQ Delisting Notification
LEXINGTON, Mass., March 4, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) announced today that the company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (the "Staff") on March 3, 2011 indicating that the company is not in compliance wi
Read more →AGENAgenus to Present at the 31st Annual Cowen and Company Health Care Conference
Agenus Inc. (Nasdaq:AGEN) announced today that Agenus management will present a corporate overview at the 31st Annual Cowen and Company Health Care Conference on Wednesday, March 9th at 8:45 am ET at the Boston Marriott Copley Place Hotel. The live and archived webcast of the co
Read more →AGENAgenus Restructures Its Remaining Convertible Notes
LEXINGTON, Mass., Feb. 24, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) announced today that it has restructured and extended the maturity of its 8.00% senior secured convertible notes to August 31, 2014. These notes have an aggregate current principal amount of $34 million
Read more →AGENAgenus Reports Fourth Quarter and Year End 2010 Financial Results
Agenus Inc. (Nasdaq:AGEN) reported today its results for the fourth quarter and year ended December 31, 2010. The company incurred a net loss attributable to common stockholders of $2.6 million, or $0.03 per share, basic and diluted, for the fourth quarter of 2010, compared with
Read more →AGENAgenus to Report Fourth Quarter and Year-End 2010 Financial Results on February 17, 2011; Conference Call to Follow
LEXINGTON, Mass., Feb. 10, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its fourth quarter and full-year financial results before the market opens on February 17, 2011. Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To
Read more →AGENAgenus Announces Research Collaboration With Memorial Sloan-Kettering Cancer Center
LEXINGTON, Mass., Jan. 24, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced it has entered into a research agreement with Memorial Sloan-Kettering Cancer Center (MSKCC) using Agenus' proprietary cancer vaccine technology. The collaboration will test Agenus' can
Read more →AGENAgenus Regains Compliance With NASDAQ Listing Requirements
LEXINGTON, Mass., Jan. 14, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) (formerly Antigenics Inc.) today announced that it has received notice from the Listing Qualifications Staff of The NASDAQ Stock Market LLC ("NASDAQ") that the company has regained compliance with Nasda
Read more →Competitive Position
How AGEN ranks across every disease it competes inCompetitive Position is a premium feature
See how AGEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial